Skip to main content
. 2023 May 17;20(7):739–776. doi: 10.1038/s41423-023-01032-x

Table 7.

Overview of selected clinical studies of agents targeting chemokines and receptors

Target Drug Mechanism of Action NCT Status Condition or Disease Phase
CCR2/CCR5 Cenicriviroc (CVC) (TAK-652; TBR-652) dual antagonist of CCR2/CCR5 NCT04593940 Completed Covid19 Phase 3
CCR4 Mogamulizumab (KW-0761) humanized monoclonal antibody that binds to CCR4 NCT01728805 Completed Cutaneous T-Cell Lymphoma Phase 3
CCR5 Vicriviroc antagonist of CCR5 NCT00523211 Completed HIV Infections|Acquired Immunodeficiency Syndrome Phase 3
NCT00474370 Completed HIV Infections|Acquired Immunodeficiency Syndrome Phase 3
CCR5 Maraviroc CCR5 antagonist NCT02881762 Completed Hepatitis C|Human Immunodeficiency Virus Phase 4
NCT02159027 Completed AIDS Dementia Complex Phase 2|Phase 3
NCT01389063 Unknown Endothelial Dysfunction Phase 4
NCT01866267 Completed Human Immunodeficiency Virus|AIDS Phase 4
NCT01190293 Completed HIV Infection Phase 4
NCT01449006 Completed Human Immunodeficiency Virus (HIV) | HIV Associated Neurocognitive Disorders (HAND) Phase 4
NCT03402815 Completed HIV Infection With Other Conditions|Cardiovascular Risk Factor|Atherosclerosis|Inflammation Phase 4
NCT01235013 Unknown HIV-1 Infection Phase 4
NCT01348308 Completed HIV-1 Infection|AIDS Phase 3
NCT00884858 Completed HIV Infections Phase 4
NCT00666705 Completed Healthy Phase 4
NCT00735072 Completed HIV Infection Phase 4
NCT00853840 Completed AIDS Phase 4
NCT01896921 Completed HIV Phase 3
NCT00875368 Completed HIV Infections Phase 4
NCT03178084 Completed HIV/AIDS Phase 3
NCT01327547 Completed HIV Coinfection Phase 4
NCT01384682 Completed HIV Phase 4
NCT00966329 Completed HIV | HIV Infections Phase 4
NCT01275625 Completed HIV Phase 4
NCT00870363 Completed HIV Infections Phase 4
NCT00426660 Completed HIV Infections Phase 3
NCT01680536 Completed HIV Phase 4
NCT03129113 Completed Hepatic Steatosis|HIV-1-infection Phase 2|Phase 3
NCT01013987 Unknown HIV-1 Adults Patients|AIDS|Triple Class Failure Phase 4
NCT00478231 Completed Acquired Immunodeficiency Syndrome|HIV Infection Phase 3
NCT00925756 Completed HIV Infections Phase 4
NCT00808002 Completed HIV Infections Phase 3
NCT00844519 Completed HIV Infection|Cardiovascular Disease|Inflammation|HIV Infections Phase 3
NCT01533272 Completed HIV Infection Phase 4
NCT00717067 Completed Human Immunodeficiency Virus (HIV) Infection Phase 4
NCT02519777 Completed HIV Infections Phase 4
NCT01060618 Completed HIV Infections Phase 2|Phase 3
NCT00098293 Completed HIV-1 Phase 3
NCT00098722 Completed HIV Infections Phase 2|Phase 3
NCT00098306 Completed HIV Infections Phase 2|Phase 3
NCT00098748 Completed HIV Infections Phase 2|Phase 3
NCT03218592 Completed HIV/AIDS Phase 4
NCT01154673 Completed Acute HIV Infection Phase 2|Phase 3
NCT01637259 Completed Proteinuria|HIV Phase 4
NCT01367236 Completed HIV|Impaired Cognition Phase 4
NCT04965662 Completed HIV-1-infection Phase 4
NCT01033760 Completed HIV-1 Infections Phase 3
NCT01378910 Completed HIV Phase 4
NCT00935480 Completed HIV Infections Phase 3
NCT00624195 Completed HIV Infections Phase 2|Phase 3
NCT02302547 Completed HIV Phase 3
NCT02588820 Unknown HIV Infections Phase 3
NCT00537394 Completed HIV Infections Phase 3
NCT02016924 Recruiting Acquired Immune Deficiency Syndrome (AIDS) | HIV Infections Phase 2|Phase 3
NCT03631732 Completed HIV-1 Infection Phase 3
NCT02121795 Completed HIV-1 Infection Phase 3
NCT02469246 Completed HIV-1 Infection Phase 3
NCT00708162 Completed HIV Infection Phase 3
NCT02859961 Active, HIV Phase 2|Phase 3
CCR5 Leronlimab (PRO140) a humanized monoclonal antibody to CCR5 NCT04901676 Suspended COVID-19 Pneumonia Phase 3
NCT04901689 Suspended COVID-19 Pneumonia Phase 3
NCT03902522 Active, HIV-1-infection Phase 2|Phase 3
NCT02859961 Active, HIV Phase 2|Phase 3
NCT02990858 Active, Hiv|Human Immunodeficiency Virus Phase 2|Phase 3
NCT02483078 Completed HIV Phase 2|Phase 3
NCT05271370 Active, HIV-1-infection Phase 2|Phase 3
CCR9 Vercirnon (CCX282-B; GSK1605786) antagonist of CCR9 NCT01277666 Completed Crohn’s Disease Phase 3
CXCR1/CXCR2 Ladarixin dual CXCR1 and CXCR2 antagonist NCT04628481 Recruiting Drug: Ladarixin|Drug: Placebo Phase 3
CXCR1/CXCR2 Reparixin CXCR1/2 antagonist NCT05254990 Recruiting COVID-19 Pneumonia|Sars-CoV-2 Infection Phase 3
NCT04878055 Completed Pneumonia, Viral Phase 3
NCT01967888 Completed Pancreatectomy for Chronic Pancreatitis Phase 2|Phase 3
NCT01817959 Completed Islet Transplantation in Diabetes Mellitus Type 1 Phase 3
CXCR4 Plerixafor (SDZ-SID-791; JLK-169; SID-791; AMD3100, AMD-3100, JM-3100, JM 3100; trade name Mozobil) antagonist of CXCR4 NCT02056210 Completed Diabetes Phase 4
NCT05087212 Recruiting Autologous Haematopoietic Stem Cell Transplant Phase 4
NCT00838357 Completed Lymphoma (Non-Hodgkin’s Lymphoma)|Hodgkin’s Disease or Multiple Myeloma|Front Line Mobilization|Transplantation Phase 3
NCT01164475 Completed Non-Hodgkin’s Lymphoma Phase 4
NCT02006225 Unknown Autologous Stem Cell Transplantation Phase 4
NCT01767714 Completed Non-Hodgkin’s Lymphoma Phase 3
NCT02231879 Completed Myelokathexis|Infections|Neutropenia|Warts|Hypogammaglobulinemia Phase 2|Phase 3
NCT00103662 Completed Multiple Myeloma Phase 3
NCT00103610 Completed Lymphoma, Non-Hodgkin Phase 3
NCT01146834 Completed Multiple Myeloma Phase 3
NCT04000698 Recruiting Refractory Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia Phase 3
NCT04293185 Recruiting Sickle Cell Disease Phase 3
CXCR4 AMD-070 (AMD11070; AMD070; X4P-001; Mavorixafor) antagonist of CXCR4 NCT03995108 Active, WHIM Syndrome Phase 3
BL-8040 (Motixafortide; TF-14016; BKT-140; T-140) antagonist/inhibitor of CXCR4 NCT03246529 Active, Multiple Myeloma Phase 3
CXCR4 POL6326 (Balixafortide TFA) CXCR4 Antagonist NCT03786094 Active, Metastatic Breast Cancer|Locally Recurrent Breast Cancer Phase 3
CCL5 OTR4120 (CACICOL20) Glycomimetic NCT02119039 Completed Keratoconus Phase 4

Data source: clinicaltrials.gov (https://www.clinicaltrials.gov/). The selected drug was ongoing over phase III or completed. In the column of NCT, green: completed; black: ongoing

In the column of mechanism, bold black: antagonist, bold blue: antibody